ArticleJHEP reports : innovation in hepatology2025
All-cause and disease-specific mortality in young adults with MASLD: A nationwide cohort study.
Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Evaluating Outcomes in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease and Vitamin D Deficiency.Diseases (Basel, Switzerland) · 2026Article
- Correspondence to editorial 1 on "Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis".Clinical and molecular hepatology · 2026Article
- Prediction of trajectories and outcomes in early-stage metabolic dysfunction-associated steatotic liver disease: a narrative review.EClinicalMedicine · 2026Review
- Association of the atherogenic index of plasma combined with obesity indices with cardiovascular disease and mortality.Lipids in health and disease · 2026Article
- Associations between steatotic liver disease subtypes and incident diabetes in young Korean adults: A nationwide cohort study.Diabetes, obesity & metabolism · 2026Article
- Integrated metabolomics analysis identifies distinct amino acid signatures in chronic hepatitis B patients with metabolic dysfunction-associated steatotic liver disease.Frontiers in cellular and infection microbiology · 2026Article
- Association between atherogenic index of plasma (AIP) and all-cause and cardiovascular mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a cohort study based on NHANES 1999-2018.Cardiovascular diabetology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a major cause of chronic liver disease globally, particularly among young adults. We aimed to analyze all-cause and disease-specific mortality in young adults with MASLD. Methods: In this nationwide cohort study, we analyzed data from the Korean National Health Insurance Service, focusing on individuals aged 20 to 39 years who underwent health screenings between 2009 and 2012. The participants were categorized into two groups: those with MASLD and those without steatotic liver disease (SLD). SLD was defined by a fatty liver index ≥30. Mortality risk was analyzed via Cox proportional hazards models. Results: A total of 5,699,047 participants were included in the study, 25.4% of whom had MASLD. During a median follow-up of 10.6 years (interquartile range, 9.5-11.2), all-cause death occurred in 11,706 (0.8%) participants in the MASLD group and in 19,611 (0.5%) in the non-SLD group. Young adults with MASLD had a significantly greater risk of all-cause mortality than those without steatosis (adjusted hazard ratio [aHR], 1.15; 95% CI 1.12-1.19). The MASLD group also had an increased risk of mortality related to cardiovascular disease, liver cancer, and liver disease, whereas the risk of extrahepatic cancer-related mortality did not significantly differ between the two groups. Compared to men with MASLD, women with MASLD had higher risks of all-cause, cardiovascular, extrahepatic cancer, and liver disease-related mortality, although the risk of liver cancer-related mortality was similar between the sexes. Conclusion: Young adults with MASLD are at a significantly increased risk of all-cause and disease-specific mortality. These findings underscore the importance of early detection and intervention to mitigate the long-term outcomes of MASLD in young adults. Impact and implications: Global increases in obesity among adolescents and young adults are driving an increase in the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in these populations. In this nationwide cohort study, young adults with MASLD were found to have a significantly greater risk of all-cause mortality, as well as mortality related to cardiovascular disease, liver cancer, and liver disease than those without steatosis. Therefore, early detection and timely intervention for MASLD in young adults are crucial to improving clinical outcomes and reducing the global burden of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.